Caplin Point re-appoints Dr Sridhar Ganesan as MD; CFO gets WTD role

Management Changes View source PDF Explain this filing

CAPLIPOINT · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-6.3%Reaction day

₹2630.00

prior close

₹2478.70

announcement price

In-mkt

timing

Nifty Smallcap 250market-0.3%-6.1% vs market

Pharmaceuticals peers, median of 165sector-0.6%-5.8% vs sector

On the reaction day the stock moved 6.1 pts less than Nifty Smallcap 250 and 5.8 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

+0.4

15m

+0.0

30m

-0.6

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-6.3-0.3-6.1-0.6-5.8

Next day

-4.8-0.1-4.7-0.3-4.5

-5.4-0.6-4.8-0.6-4.7

-4.0-0.4-3.6-1.4-2.6

-3.8-0.2-3.6-1.1-2.7

-2.1-0.8-1.3-1.9-0.2

-2.3+0.2-2.5-1.2-1.1

15d

+3.4-0.7+4.1-1.0+4.4

-2.2-2.7+0.5-0.2-2.0

-7.7-3.3-4.4-3.2-4.5

—————

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 165Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Caplin Point Laboratories has re-appointed Dr. Sridhar Ganesan as Managing Director for 2 years effective August 25, 2026. Separately, existing CFO Mr. D. Muralidharan has been additionally appointed as Whole-Time Director for 2 years from August 12, 2026, while continuing as CFO. Both appointments are subject to shareholder approval at the next AGM.

Likely market impact

Leadership continuity. CFO joining the board signals stronger finance oversight. Both moves need shareholder approval at the AGM.